Sort by regulatory status before anything else. Everything sold as a peptide falls into one of three groups: FDA-approved medicines with a published label, compounded versions of those approved molecules, and unapproved compounds sold on mechanism stories. That single sort settles most of the comparison, because only the first group is required to show human outcome evidence.
Why a ranked list is the wrong instrument
No federal agency ranks peptides. There is no scored register, no official best-of, and no body that certifies one compound as superior to another for general wellness use. Every ranking a reader meets was authored by someone, and the author usually sells something.
What does exist is a public record anyone can open: approval status, product labels on DailyMed, published trials, and a federal page naming bulk substances flagged for safety concerns in compounding. That record supports a checklist. It does not support a leaderboard.
Check one: does an approved product containing this molecule exist
This is the most decisive question, and it takes about a minute on DailyMed. If a label comes back, the molecule cleared a review of safety, effectiveness, and manufacturing quality for a stated indication. If nothing comes back, no such review happened, whatever the marketing implies.
The approved list is smaller than most articles suggest and stranger than most readers expect. Semaglutide appears under Wegovy, whose current label covers both an injection and a tablet, and separately under Ozempic and Rybelsus for type 2 diabetes. Tirzepatide appears under Zepbound, which carries a second indication for moderate to severe obstructive sleep apnea in adults with obesity. Tesamorelin, a growth hormone releasing factor analog, is approved only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, and its label states plainly that it is not indicated for weight loss management. Setmelanotide is approved for named genetic and hypothalamic causes of obesity. Orforglipron, approved in April 2026 as FOUNDAYO, reaches the same receptor as the injectable drugs but is an oral small molecule rather than a peptide, which is worth knowing before it gets filed under peptides by a shopping guide.
Check two: place the compound in the right tier
| Compound | Regulatory status | Evidence class |
|---|---|---|
| Semaglutide (Wegovy) | FDA-approved; label now covers injection and tablet | Large randomized trials with prespecified weight endpoints |
| Tirzepatide (Zepbound) | FDA-approved for obesity and for moderate to severe obstructive sleep apnea with obesity | Large randomized trials in each indication |
| Orforglipron (FOUNDAYO) | FDA-approved April 2026; oral small molecule, not a peptide | Published phase 2 and phase 3 results |
| Tesamorelin (Egrifta SV) | FDA-approved, narrow indication in HIV-associated lipodystrophy | Randomized trials confined to that population |
| Setmelanotide (Imcivree) | FDA-approved for specified genetic and hypothalamic obesity | Trials in the named genotypes |
| Compounded semaglutide or tirzepatide | Not FDA-approved as a product; prepared by a licensed pharmacy for an identified patient | Trial evidence belongs to the approved product, not to the preparation |
| BPC-157 | No approved product; nomination for compounding withdrawn after FDA flagged concerns | FDA identified no, or only limited, safety information for the proposed routes |
| TB-500 (thymosin beta-4 fragment) | No approved product; nomination withdrawn | FDA states it has not identified any human exposure data |
| Ipamorelin acetate | No approved product; category 2 under the 503B interim policy | FDA cites serious adverse events including death from intravenous use for gastric motility |
Check three: search the compounding safety page by name
The FDA maintains a page listing bulk drug substances that may present significant safety risks in compounding, split into substances currently in category 2 and substances whose nominations were withdrawn. A striking share of the peptide market appears on it. GHRP-2, GHRP-6, ibutamoren, ipamorelin acetate, and kisspeptin-10 sit in category 2. BPC-157, CJC-1295, AOD-9604, epitalon, melanotan II, MOTS-c, selank, semax, PEG-MGF, KPV, and TB-500 appear among the withdrawn nominations, each with the agency’s stated reason attached.
The reasons repay reading. Several entries say the same thing in the same language: the agency has not identified any human exposure data by any route, so it cannot judge whether the substance would cause harm. For melanotan II the entry is more specific, citing published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism.
Reading provider sites through the same filter is quick work. The cash-pay telehealth field is crowded, with Ro, Hims and Hers, Henry Meds, and HealthRX all maintaining public pages, and the ones that hold up separate approved medicines from compounded and unapproved compounds instead of blending them. HealthRX organizes its peptide therapy information around what a clinician can prescribe, which is a claim a reader can check, while thinner sites lean on mechanism language. Run several past the approval question and the difference shows immediately.
Check four: match the verb to the evidence
Marketing copy in this category leans on mechanism verbs. A compound upregulates a pathway, activates a receptor, or signals a repair process. Those verbs describe what happens in a dish or a rodent. Outcome verbs, meaning reduced, improved, or increased, belong to measured results in people, and they are the ones that go missing when the human literature is thin.
Applying this filter is unglamorous and effective. Tirzepatide earns an outcome verb because a randomized trial measured body weight against placebo. BPC-157 marketing uses outcome verbs too, but the studies underneath are rat models.
Check five: identify who prescribes and who dispenses
Tier decides the supply route. An approved product comes from a licensed pharmacy against a prescription. A compounded version of an approved molecule comes from a 503A pharmacy or a 503B outsourcing facility, still through a prescriber, and is not FDA-approved. An unapproved research compound usually arrives from a vendor that is not a pharmacy at all, labeled for laboratory use, with no prescriber anywhere in the transaction.
Among physician-supervised services that dispense compounded versions of approved molecules, Hims, Ro, Noom, and FormBlends all operate on the same basic model: a clinician reviews an intake, a partner pharmacy prepares the medication, and the patient pays cash because compounded preparations are generally not covered by insurance or Medicare Part D. The model is legitimate and the product is still not FDA-approved. Both facts are true at once, and a fair comparison holds both.
Frequently asked questions
Is pharmaceutical grade a regulatory category?
No. The phrase has no definition in federal drug law and no agency issues it. Approved products are described by their application number and label, not by a grade. When a vendor with no approved product uses the term, it is a marketing word standing in for a status the product does not hold.
Does a pharmacy preparing something mean the FDA reviewed it?
No. Compounding is a supply mechanism that lets a licensed pharmacy prepare a medication for an identified patient. The FDA does not review compounded preparations for safety, effectiveness, or manufacturing quality before they are dispensed. Pharmacy involvement raises the floor on handling and oversight without conferring approval.
What does research use only on a vial actually mean?
It means the seller is not claiming the contents are a drug for human use, which removes them from the prescription drug framework. There is no prescriber, no dispensing pharmacist, no required sterility or potency standard, and no recall pathway. The label is a legal position, not a quality statement.
Why does BPC-157 top so many lists?
Because the preclinical literature is unusually broad and unusually positive, and because no approved competitor exists to contradict it. Volume of publication is not the same as strength of evidence. The FDA record notes that it identified no, or only limited, safety-related information for the routes people actually use.
Should orforglipron be compared alongside peptides at all?
It reaches the same receptor as semaglutide, so functionally it belongs in the same shopping comparison. Chemically it does not, since it is a small molecule taken by mouth rather than a peptide. Anyone comparing on evidence rather than chemistry can include it, provided the difference is stated.
